During the past decade, Studienzentrum Onkologie Ravensburg conducted 23 clinical trials. In the 10-year time frame, 23 clinical trials started and 3 clinical trials were completed, i.e. on average, 13% percent of trials that started reached the finish line to date. In the past 5 years, 11 clinical trials started and 2 clinical trials were completed. i.e. 18.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Studienzentrum Onkologie Ravensburg" #1 sponsor was "German CLL Study Group" with 3 trials, followed by "Hoffmann-La Roche" with 3 trials sponsored, "Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest" with 3 trials sponsored, "AGO Research GmbH" with 2 trials sponsored and "German Breast Group" with 2 trials sponsored. Other sponsors include 11 different institutions and companies that sponsored additional 21 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Studienzentrum Onkologie Ravensburg" #1 collaborator was "Hoffmann-La Roche" with 4 trials as a collaborator, "Cancer Trials Ireland" with 3 trials as a collaborator, "Arbeitsgemeinschaft Gynaekologische Onkologie Austria" with 2 trials as a collaborator, "European Network of Gynaecological Oncological Trial Groups (ENGOT)" with 2 trials as a collaborator and "Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest" with 2 trials as a collaborator. Other collaborators include 50 different institutions and companies that were collaborators in the rest 57 trials.

According to Clinical.Site data, the most researched conditions in "Studienzentrum Onkologie Ravensburg" are "Ovarian Cancer" (4 trials), "Colorectal Cancer" (3 trials), "Chronic Lymphocytic Leukemia" (2 trials), "Chronic Lymphoid Leukemia" (2 trials) and "Fallopian Tube Cancer" (2 trials). Many other conditions were trialed in "Studienzentrum Onkologie Ravensburg" in a lesser frequency.

Most popular intervention types in "Studienzentrum Onkologie Ravensburg" are "Drug" (26 trials) and "Biological" (4 trials). Other intervention types were less common.

The name of intervention was led by "Bevacizumab" (3 trials), "Carboplatin" (3 trials), "Cyclophosphamide" (3 trials), "Obinutuzumab" (3 trials) and "Paclitaxel" (3 trials). Other intervention names were less common.

The vast majority of trials in "Studienzentrum Onkologie Ravensburg" are 20 trials for "All" genders and 9 trials for "Female" genders.

Currently, there are NaN active trials in "Studienzentrum Onkologie Ravensburg". undefined are not yet recruiting, 7 are recruiting, 14 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in Studienzentrum Onkologie Ravensburg, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Studienzentrum Onkologie Ravensburg, 0 "Phase 1" clinical trials were conducted, 9 "Phase 2" clinical trials and 18 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".

Studienzentrum Onkologie Ravensburg has several departments that took part in Clinical trials: "Hämatologisch/Onkologische Praxis Prof. Dr. Decker, Studienzentrum" - 2 trials